블로그

CIDP

AIDP vs. CIDP: Unraveling the Similarities and Differences

Man suffering from muscle tingling and pain from AIDP

Acute Inflammatory Demyelinating Polyneuropathy (AIDP) and 만성 염증성 탈수초성 다발신경병증(CIDP) are both neurological disorders in which the body’s immune system attacks its own nerves and can lead to paralysis. While both disorders have similar symptoms, they differ in duration and progression. Understanding the differences can be crucial for your treatment of these disorders.

IVIG 공제금 지원 받기 | IVIG 재정 지원

(877) 778-0318

What Is Acute Inflammatory Demyelinating Polyneuropathy (AIDP)?

Acute inflammatory demyelinating polyneuropathy (AIDP) is an autoimmune disorder. It occurs when your body’s immune system mistakenly attacks your peripheral nerves’ protective myelin sheath. This leads to muscle weakness, tingling, and paralysis. AIDP is the most common form of 길랭-바레 증후군, and its exact cause is not fully understood. 

만성 염증성 탈수초 다발신경병증(CIDP)이란?

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is another rare type of autoimmune disorder. CIDP affects only 2 to 3 per 100,000 people every year. In this condition, the immune system attacks the peripheral nerves’ myelin sheath over an extended period. It can also cause weakness and paralysis. This condition is more chronic or long-term than AIDP.  

What Causes AIDP and CIDP?

The exact causes of  AIDP and CIDP are unknown. They are both autoimmune diseases where the immune system mistakenly targets and damages the myelin sheath surrounding peripheral nerves. 

Approximately 60 percent of AIDP cases occur suddenly after an infection, vaccination, or surgery [1]. On the other hand, CIDP develops slowly over time, and it does not have any connection to an infection. Both conditions affect the nerves, causing weakness and paralysis to some degree. Scientists are researching why this occurs and how to treat these conditions. 

Symptoms of AIDP vs. CIDP

AIDP

The symptoms of AIDP are consistent across all age groups, yet specific symptoms may differ for each person. These are some possible symptoms of AIDP:

  • A sudden onset of weakness 
  • A sensation of tingling and numbness
  • Loss of muscle control
  • 통증
  • Perception of touch and other sensations may be affected
  • Paralysis of the legs, arms, and face impacting daily activities
  • In critical situations, respiratory muscles may be impacted, requiring urgent medical attention

Most people experience symptoms that worsen for up to 4 weeks before stabilizing and eventually improving.

CIDP

Symptoms of CIDP develop slowly over time. It is more progressive than AIDP. The most common symptom of CIDP is muscle weakness that worsens over at least 8 weeks. Other symptoms of CIDP include:

  • 따끔거림과 무감각
  • 반사신경 상실
  • Loss of balance and walking ability
  • In some cases, speaking and swallowing difficulties
  • 복시
  • 통증
  • Loss of muscle mass in affected muscles
  • 피로

These symptoms may change in severity over time. Early diagnosis and therapy are critical for successful disease management. 

Diagnosis of AIDP vs. CIDP

The symptoms of AIDP and CIDP are very similar. Because of this, it is very difficult to differentiate between AIDP vs. CIDP at first. Doctors often confuse the symptoms of CIDP with those of AIDP. 

The diagnosis of AIDP and CIDP involves considering the onset, duration, and progression of symptoms. These are key points that are useful in the diagnosis of AIDP and CIDP:

  • Disease Onset: AIDP occurs suddenly, typically after an infection, surgery, or vaccination. On the other hand, CIDP has a gradual onset, evolving over at least eight weeks. 
  • Disease Progression: In AIDP, 에스ymptoms of weakness and numbness progress rapidly over days to weeks. Disease progression is slower in CIDP. If symptoms last more than 8 weeks, then the doctor may suspect CIDP.
  • History of Infection: AIDP often follows an infection, while CIDP has no clear link to an infection.
  • Nerve Conduction Velocity (NCV) and Electromyography (EMG): These specialized tests can show characteristic patterns of nerve dysfunction, which plays a key role in the diagnosis of AIDP and CIDP.

공제금 지원에 대해 전문가와 상담하세요

상담 일정을 잡으세요

Treatment of AIDP vs. CIDP

Bag of plasma being used for plasma exchange

There are several strategies to treat AIDP and CIDP. Among them, immunoglobulin therapy is the most effective one. Here are the most common treatment options:

Treatment of AIDP

AIDP is most commonly treated with intravenous immunoglobulin (IVIG) and plasmapheresis (plasma exchange) [3]. IVIG helps to reduce inflammation, accelerating recovery. Plasmapheresis is a procedure that replaces blood plasma to eliminate harmful antibodies that cause nerve damage. 

The treatment also involves the use of pain management medications and physical therapy. In severe cases, patients might need ventilation support. 

Treatment of CIDP

The common treatment options for CIDP include intravenous immunoglobulin (IVIG), plasma exchange (PE), steroids, and immunosuppressant drugs [2]. Physical therapy is also useful for patients with CIPD. Doctors may also prescribe pain management medications.

CIDP is a chronic condition that often requires long-term management. Your medical team customizes your treatment for you and regularly monitors your progress.  

자주 묻는 질문

Here are some frequently asked questions about AIDP and CIDP:

1. Can I Fully Recover From CIDP?

Early detection and treatment can improve your balance, strength, and quality of life. CIDP requires long-term treatment. Sometimes, your symptoms may disappear for a while and then worsen again. People may recover entirely from CIDP, but they may have signs of nerve damage like numbness and weakness for the rest of their lives.

2. How Long Does It Take To Recover From AIDP?

With proper treatment, recovery can take months to a year. About 77 percent of patients can walk independently within 6 months [3]. However, for some people, recovery can take up to 3 years. 

3. Can AIDP or CIDP Recur?

AIDP is typically a one-time occurrence. However, CIDP can be chronic and recurring. Some people with CIDP may have periods of recovery followed by relapse. 

참고문헌:

  1. Peripheral demyelinating and axonal disorders. (n.d.). https://collections.lib.utah.edu/dl_files/c6/02/c602fcad35455a41a40effc0494d3a2dfe40eeb8.pdf 
  2. Oaklander, A. L., Lunn, M. P., Hughes, R., Van Schaik, I. N., Frost, C., & Chalk, C. (2017). Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. The Cochrane Library, 2017(1). https://doi.org/10.1002/14651858.cd010369.pub2
  3. Knadmin. (2023, December 13). AIDP/CIDP Part 2: Treatment. PM&R KnowledgeNow. https://now.aapmr.org/aidpcidp-part-2-treatment/
이 정보는 의학적 조언이나 치료를 대체할 수 없습니다. 새로운 치료를 시작하기 전에 담당 의사 또는 의료 서비스 제공자와 건강 상태에 대해 상담하십시오. AmeriPharma® Specialty Care는 제공된 정보 또는 그 결과로 내려진 진단이나 치료에 대해 어떠한 책임도 지지 않으며, 콘텐츠의 신뢰성에 대해서도 책임을 지지 않습니다. AmeriPharma® Specialty Care는 여기에 나열된 모든 웹사이트/기관을 운영하는 것은 아니며, 해당 콘텐츠의 가용성이나 신뢰성에 대해서도 책임을 지지 않습니다. 이러한 목록은 AmeriPharma® Specialty Care의 보증, 후원 또는 추천을 암시하거나 구성하지 않습니다. 이 웹페이지에는 AmeriPharma® Specialty Care와 제휴하지 않은 제약 회사의 상표 또는 등록 상표인 브랜드 처방약에 대한 참조가 포함될 수 있습니다.
의학적으로 검토됨 Christine Leduc 박사, PharmD

크리스틴 레덕 약학박사는 캘리포니아주 어바인에서 태어나고 자랐습니다. 미드웨스턴 대학교를 우등으로 졸업했습니다. 그녀의 업무에서 가장 보람 있는 부분은 생활 습관 변화를 제안하고, 환자에게 약물의 작용 원리를 교육하고, 미래의 약사들을 지도하는 것입니다. 그녀의 전문 분야는 고객 서비스와 특수 약물에 대한 지식입니다. 과거 서비스 업계에서 일한 경험을 통해 환자의 요구를 이해하는 데 필요한 고객 서비스 기술을 습득했습니다. 레덕 박사는 현재 마셜 B. 케첨 대학교, 캔자스 대학교, 미드웨스턴 대학교에서 학생들을 지도하고 있습니다. 여가 시간에는 여행, 베이킹, 정원 가꾸기를 즐깁니다. 저자 약력 보기

문의하기

아래 HIPAA 규격 양식을 사용하여 처방전 재조제를 요청하세요. 복용 중인 약이나 복용 방법에 대한 문의 사항이 있으시면 문의하기 페이지를 방문하시거나 다음 번호로 전화해 주세요. (877) 778-0318.

HIPAA Compliant

제출하면 AmeriPharma에 동의하는 것입니다. 이용 약관, 개인정보 보호정책, 그리고 개인정보 보호 관행 고지

ko_KRKorean